PATH Stock Will Have a HUGE Rebound: Here’s Why | UiPath Stock Analysis скачать в хорошем качестве

PATH Stock Will Have a HUGE Rebound: Here’s Why | UiPath Stock Analysis

UiPath stock has collapsed over 30 percent in the last month and nearly 50 percent from its highs but the fundamentals tell a very different story. In this video, I break down why UiPath’s latest agentic AI launch in healthcare could be a turning point for the business and why this selloff may be overdone. We dive into how UiPath is automating revenue cycle management, medical record summarization, claim denial prevention, and prior authorization in one of the most complex and regulated industries in the world. I also explain UiPath’s powerful enterprise partnerships with Google Cloud, NVIDIA, Microsoft, Snowflake, OpenAI, and Inflection AI and why these relationships position UiPath as the orchestration layer for agentic AI rather than just another automation tool. Finally, I walk through my 12 month price target of $21 and clearly outline what needs to happen for UiPath to get there including revenue re acceleration, ARR growth, expanding profitability, and market re rating. This is not hype driven AI. This is operational automation tied directly to revenue, compliance, and enterprise demand. Let me know your UiPath price target in the comments and whether you want a deeper valuation breakdown next.